Drugs / CD62L- Tem
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03836690 | Oct 2019 → Jul 2022 | aplastic anemia, graft versus host disease, immunodeficiency disease, leukemia +2 | University College, London | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD62L- Tem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03836690 ↗ |
| Modality | Cell therapy | “infusion of donor CD62L- effector memory T cells” NCT03836690 ↗ |